The therapeutic potential of agents targeting the type I insulin-like growth factor receptor

Expert Opinion on Investigational Drugs

Volumn 13, Issue 12, 2004, Pages 1569-1577

  Zhang, Hua ^b   Yee, Douglas ^a  

^a UNIVERSITY OF MINNESOTA   (United States)

^b NONE

Author keywords

Cancer; IGF 1; IGF 1R; IGF 2; IGFBPs; Insulin; Insulin receptor

Indexed keywords

ANTINEOPLASTIC AGENT; ANTISENSE OLIGONUCLEOTIDE; CETUXIMAB; COMPLEMENTARY RNA; CP 751871; CYCLOLIGNAN DERIVATIVE; CYTOTOXIC AGENT; INSULIN; INSULIN RECEPTOR; LIGAND; MESSENGER RNA; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY A12; MONOCLONAL ANTIBODY H7C10; NVP ADW 742; NVP AEW 541; PICROPODOPHYLLIN; PYRIMIDINE DERIVATIVE; RECEPTOR ANTIBODY; RECEPTOR BLOCKING AGENT; RECOMBINANT INSULIN GROWTH FACTOR BINDING PROTEIN; SMALL INTERFERING RNA; SOMATOMEDIN B; SOMATOMEDIN C; SOMATOMEDIN C RECEPTOR; SOMATOMEDIN C RECEPTOR ANTIBODY; SOMATOSTATIN DERIVATIVE; TAMOXIFEN; TRASTUZUMAB; UNCLASSIFIED DRUG; UNINDEXED DRUG; VIRUS VECTOR;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; BREAST CANCER; CANCER CELL; CANCER GROWTH; CANCER INHIBITION; CARCINOGENESIS; CELL MOTILITY; CLINICAL TRIAL; DRUG HALF LIFE; DRUG TARGETING; DRUG TOLERABILITY; ENZYME ACTIVITY; FIBROSARCOMA; HUMAN; LIVER CANCER; MALIGNANT TRANSFORMATION; MELANOMA; METASTASIS; NONHUMAN; PHENOTYPE; PROSTATE CANCER; PROTEIN EXPRESSION; PROTEIN FUNCTION; RECEPTOR INTRINSIC ACTIVITY; REGULATORY MECHANISM; REVIEW; SIDE EFFECT; SIGNAL TRANSDUCTION; TUMOR XENOGRAFT; VIRAL GENE DELIVERY SYSTEM;

ANTINEOPLASTIC AGENTS; GENE EXPRESSION; HUMANS; INSULIN-LIKE GROWTH FACTOR I; NEOPLASMS; RECEPTOR, IGF TYPE 1; SIGNAL TRANSDUCTION;

EID: 10344222098     PISSN: 13543784     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543784.13.12.1569     Document Type: Review

References (100)

1. MENDELSOHN J, BASELGA J: The EGF receptor family as targets for cancer therapy. Oncogene (2000) 19:6550-6565.
2. RAYMOND E, FAIVRE S, ARMAND JP: Epidermal growth factor receptor tyrosine kinase as a target for anticancer therapy. Drugs (2000) 60(Suppl. 1):15-23.
3. FUKUOKA M, YANO S, GIACCONE G et al.: Multi-institutional randomized Phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer. J. Clin. Oncol. (2003) 21:2237-2246.
4. PAEZ JG, JANNE PA, LEE JC et al.: EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science (2004) 304:1497-1500.
5. ULLRICH A, GRAY A, TAM AW et al.: Insulin-like growth factor I receptor primary structure: comparison with insulin receptor suggests structural determinants that define functional specificity. Embo. J. (1986) 5:2503-2512.
6. SEPP-LORENZINO L: Structure and function of the insulin-like growth factor I receptor. Breast Cancer Res. Treat. (1998) 47 235-253.
7. MOLLER DE, YOKOTA A, CARO JF, FLIER JS: Tissue-specific expression of two alternatively spliced insulin receptor mRNAs in man. Mol. Endocrinol. (1989) 3:1263-1269.
8. PAPA V, PEZZINO V, COSTANTINO A et al.: Elevated insulin receptor content in human breast cancer. J. Clin. Invest. (1990) 86:1503-1510.
9. MILAZZO G, GIORGINO F, DAMANTE G et al.: Insulin receptor expression and function in human breast cancer cell lines. Cancer Res. (1992) 52:3924-3930.
10. PANDINI G, VIGNERI R, COSTANTINO A et al.: Insulin and insulin-like growth factor-I (IGF-1) receptor overexpression in breast cancers leads to insulin/IGF-1 hybrid receptor overexpression: evidence for a second mechanism of IGF-1 signaling. Clin. Cancer Res. (1999) 5:1935-1944.
11. FRITTITTA L, SCIACCA L, CATALFAMO R et al.: Functional insulin receptors are overexpressed in thyroid tumors: is this an early event in thyroid tumorigenesis? Cancer (1999) 85:492-498.
12. VELLA V, PANDINI G, SCIACCA L et al.: A novel autocrine loop involving IGF-II and the insulin receptor isoform-A stimulates growth of thyroid cancer. J. Clin. Endocrinol. Metab (2002) 87 245-254.
13. SCIACCA L, MINEO R, PANDINI G et al.: In IGF-1 receptor-deficient leiomyosarcoma cells autocrine IGF-2 induces cell invasion and protection from apoptosis via the insulin receptor isoform A. Oncogene (2002) 21:8240-8250.
14. PANDINI G, FRASCA F, MINEO R et al.: Insulin/insulin-like growth factor I hybrid receptors have different biological characteristics depending on the insulin receptor isoform involved. J. Biol. Chem. (2002) 277:39684-39695.
15. ZHANG X, YEE D: Tyrosine kinase signalling in breast cancer: insulin-like growth factors and their receptors in breast cancer. Breast Cancer Res. (2000) 2:170-175.
16. VUORI K, RUOSLAHTI E: Association of insulin receptor substrate-1 with integrins. Science (1994) 266:1576-1578.
17. MAURO L, SALERNO M, MORELLI C et al.: Role of the IGF-1 receptor in the regulation of cell-cell adhesion: implications in cancer development and progression. J. Cell. Physiol. (2003) 194 108-116.
18. 3 integrin regulates insulin-like growth fictor I (IGF-1) receptor phosphorylation by altering the rate of recruitment of the Src-homology 2-containing phosphotyrosine phosphatase-2 to the activated IGF-1 receptor. Endocrinology (2002) 143:4259-4264.
19. PERKS CM, HOLLY JM: Insulin-like growth factor binding proteins (IGFBPs) in breast cancer. J. Mammary Gland Biol. Neoplasia (2000) 5:75-84.
20. PERKS CM, HOLLY JM: IGFBPs and breast cancer. Breast disease (2003) 17:91-104.
21. RITVOS O, RANTA T, JALKANEN J et al.: Insulin-like growth factor (IGF) binding protein from human decidua inhibits the binding and biological action of IGF-1 in cultured choriocarcinoma cells. Endocrinology (1988) 122:2150-2157.
22. BLUM WF, JENNE EW, REPPIN F et al.: Insulin-like growth factor I (IGF-1)-binding protein complex is a better mitogen than free IGF-1. Endocrinology (1989) 125:766-772.
23. MORRIONE A, VALENTINIS B, XU SQ et al.: Insulin-like growth factor II stimulates cell proliferation through the insulin receptor. Proc. Natl. Acad. Sci. USA (1997) 94:3777-3782.
24. ELLIS MJ, LEAV BA, YANG Z et al.: Affinity for the insulin-like growth factor-II (IGF-2) receptor inhibits autocrine IGF-2 activity in MCF-7 breast cancer cells. Mol. Endocrinol. (1996) 10:286-297.
25. HANKINS GR, DE SOUZA AT, BENTLEY RC et al.: M6P/IGF2 receptor: a candidate breast tumor suppressor gene. Oncogene (1996) 12:2003-2009.
26. CULLEN KJ, YEE D, SLY WS et al.: Insulin-like growth factor receptor expression and function in human breast cancer. Cancer Res. (1990) 50:48-53.
27. HELLAWELL GO, TURNER GD, DAVIES DR et al.: Expression of the type 1 insulin-like growth factor receptor is up-regulated in primary prostate cancer and commonly persists in metastatic disease. Cancer Res. (2002) 62:2942-2950.
28. SURMACZ E: Growth factor receptors as therapeutic targets: strategies to inhibit the insulin-like growth factor I receptor. Oncogene (2003) 22:6589-6597.
29. LEROITH D, ROBERTS CT Jr: The insulin-like growth factor system and cancer. Cancer Lett. (2003) 195:127-137.
30. ALMEIDA A, MULERIS M, DUTRILLAUX B, MALFOY B: The insulin-like growth factor I receptor gene is the target for the 15q26 amplicon in breast cancer. Genes Chromosomes Cancer (19 94) 11 63-65.
31. KALEKO M, RUTTER WJ, MILLER AD: Overexpression of the human insulin like growth factor I receptor promotes ligand-dependent neoplastic transformation. Mol. Cell. Biol. (1990) 10 464-473.
32. SELL C, DUMNEIL G, DEVEAUD C et al.: Effect of a null mutation of the type 1 IGF receptor gene on growth and transformation of mouse embryo fibroblasts. Mol. Cell. Biol. (1994) 14 3604-3612.
33. VALENTINIS B, PORCU P, QUINN K, BASERGA R: The role of the insulin-like growth factor I receptor in the transformation by simian virus 40 T antigen. Oncogene (1994) 9:825-831.
34. COPPOLA D, FERBER A, MIURA M et al.: A functional insulin-like growth factor I receptor is required for the mitogenic and transforming activities of the epidermal growth factor receptor. Mol. Cell. Biol. (1994) 14:4588-4595.
35. VALENTINIS B, MORRIONE A, TAYLOR SJ, BASERGA R: Insulin-like growth factor I receptor signaling in transformation by src oncogenes. Mol. Cell. Biol. (1997) 17:3744-3754.
36. LIU JL, BLAKESLEY VA, GUTKIND JS, LEROITH D: The constitutively active mutant Gα13 transforms mouse fibroblast cells deficient in insulin-like growth factor-I receptor. J. Biol. Chem. (1997) 272:29438-29441.
37. RESNICOFF M, COPPOLA D, SELL C et al.: Growth inhibition of human melanoma cells in nude mice by antisense strategies to the Type 1 insulin-like growth factor receptor. Cancer Res. (1994) 54:4848-4850.
38. RESNICOFF M, SELL C, RUBINI M et al.: Rat glioblastoma cells expressing an antisense RNA to the insulin-like growth factor-1 (IGF-1) receptor are nontumorigenic and induce regression of wild-type tumors. Cancer Res. (1994) 54:2218-2222.
39. REISS K, D'AMBROSIO C, TU X, TU C, BASERGA R: Inhibition of tumor growth by a dominant negative mutant of the insulin-like growth factor I receptor with a bystander effect. Clin. Cancer Res. (1998) 4:2647-2655.
40. SACHDEV D, LI SL, HARTELL JS et al.: A chimeric humanized single-chain antibody against the type I insulin-like growth factor (IGF) receptor renders breast cancer cells refractory to the mitogenic effects of IGF-1. Cancer Res. (2003) 63:627-635.
41. BASERGA R, PERUZZI F, REISS K: The IGF-1 receptor in cancer biology. Int. J. Cancer (2003) 107:873-877.
42. TURNER BC, HAFFTY BG, NARAYANAN L et al.: Insulin-like growth factor-I receptor overexpression mediates cellular radioresistance and local breast cancer recurrence after lumpectomy and radiation. Cancer Res. (1997) 57:3079-3083.
43. WEN B, DEUTSCH E, MARANGONI E et al.: Tyrphostin AG 1024 modulates radinsensitivity in human breast cancer cells. Br. J. Cancer (2001) 85:2017-2021.
44. REISS K, WANG JY, ROMANO G et al.: Mechanisms of regulation of cell adhesion and motility by insulin receptor substrate-1 in prostate cancer cells. Oncogene (2001) 20:490-500.
45. NOLAN MK, JANKOWSKA L, PRISCO M et al.: Differential roles of IRS-1 and SHC signaling pathways in breast cancer cells. Int. J. Cancer (1997) 72:828-834.
46. STRACKE ML, ENGEL JD, WILSON LW et al.: The type I insulin-like growth factor receptor is a motility receptor in human melanoma cells. J. Biol. Chem. (1989) 264:21544-21549.
47. JACKSON JG, ZHANG X, YONEDA T, YEE D: Regulation of breast cancer cell motility by insulin receptor substrate-2 (IRS-2) in metastatic variants of human breast cancer cell lines. Oncogene (2001) 20:7318-7325.
48. DUNN SE, EHRLICH M, SHARP NJH et al.: A dominant negative mutant of the insulin-like growth factor-I receptor inhibits the adhesion; invasion; and metastasis of breast cancer. Cancer Res. (1998) 58:3353-3361.
49. SACHDEV D, HARTELL JS, LEE AV, ZHANG X, YEE D: A dominant negative Type I insulin-like growth factor receptor inhibits metastasis of human cancer cells. J. Biol. Chem. (2004) 279:5017-5024.
50. FRASCA F, PANDINI, G, VIGNERI R, GOLDFINE ID: Insulin and hybrid insulin/IGF receptors are major regulators of breast cancer cells. Breast Disease (2003) 17:73-89.
51. GIORGINO F, BELFIORE A, MILAZZO G et al.: Overexpression of insulin receptors in fibroblast and ovary cells induces a ligand-mediated transformed phenotype. Mol. Endocrinol. (1991) 5:452-459.
52. RESNICOFF M, LI W, BASAK S et al.: Inhibition of rat C6 glioblastoma tumor growth by expression of insulin-like growth factor I receptor antisense mRNA. Cancer Immunol. Immunother. (1996) 42 64-68.
53. RESNICOFF M, TJUVAJEV J, ROTMAN HL et al.: Regression of C6 rat brain tumors by cells expressing an antisense insulin-like growth factor I receptor RNA. J. Exp. Ther. Oncol. (1996) 1 385-389.
54. SAMANI AA, FALLAVOLLITA L, JAALOUK DE, GALIPEAU J, BRODT P: Inhibition of carcinoma cell growth and metastasis by a vesicular stomatitis virus G-pseudotyped retrovector expressing type I insulin-like growth factor receptor antisense. Hum. Gene Ther. (2001) 12 1969-1977.
55. SALATINO M, SCHILLACI R, PROIETTI CJ et al.: Inhibition of in vivo breast cancer growth by antisense oligodeoxynucleotides to type I insulin-like growth factor receptor mRNA involves inactivation of ErbBs, PI-3K/Akt and p42/p44 MAPK signaling pathways but not modulation of progesterone receptor activity. Oncogene (2004) 23 5161-5174.
56. BOHULA EA, SALISBURY AJ, SOHAIL M et al.: The efficacy of small interfering RNAs targeted to the type 1 insulin-like growth factor receptor (lGF-1R) is influenced by secondary structure in the IGF-1R transcript. J. Biol. Chem. (2003) 278:15991-15997.
57. MITSIADES CS, MITSIADES NS, MCMULLAN CJ et al.: Inhibition of the insulin-like growth factor receptor-1 tyrosine kinase activity as a therapeutic strategy for multiple myeloma, other hematologic malignancies, and solid tumors. Cancer Cell (2004) 5 221-230.
58. GARCIA-ECHEVERRIA C, PEARSON MA, MARTI A et al.: In vivo antitumor activity of NVP-AEW541-A novel, potent, and selective inhibitor of the IGF-1R kinase. Cancer Cell (2004) 5:231-239.
59. BLUM G, GAZIT A, LEVITZKI A: Development of new insulin-like growth factor-1 receptor kinase inhibitors using catechol mimics. J. Biol. Chem. (2003) 278:40442-40454.
60. BLUM G, GAZIT A, LEVITZKI A: Substrate competitive inhibitors of IGF-1 receptor kinase. Biochemistry (2000) 39:15705-15712.
61. GIRNITA A, GIRNITA L, DEL PRETE F et al.: Cyclolignans as inhibitors of the insulin-like growth factor-1 receptor and malignant cell growth. Cancer Res. (2004) 64:236-242.
62. FURLANETTO RW, HARWELL SE, BAGGS RB: Effects of insulin-like growth factor receptor inhibition on human melanomas in culture and in athymic mice. Cancer Res. (1993) 53:2522-2526.
63. KANTER-LEWENSOHN L, DRICU A, WANG M et al.: Expression of the insulin-like growth factor-1 receptor and its anti-apoptotic effect in malignant melanoma: a potential therapeutic target. Melanoma Res. (1998) 8:389-397.
64. LAHM H, AMSTAD P, WYNIGER J et al.: Blockade of the insulin-like growth-factor-I receptor inhibits growth of human colorectal cancer cells: evidence of a functional IGF-2-mediated autocrine loop. Int. J. Cancer (1994) 58:452-459.
65. SCOTLANDI K, BENINI S, NANNI P et al.: Blockage of insulin-like growth factor-I receptor inhibits the growth of Ewing's sarcoma in athymic mice. Cancer Res. (1998) 58:4127-4131.
66. ARTEAGA CL, KITTEN LJ, CORONADO EB et al.: Blockade of the type I somatomedin receptor inhibits growth of human breast cancer cells in athymic mice. J. Clin. Invest. (1989) 84:1418-1423.
67. KATO H, FARIA TN, STANNARD B, ROBERTS CT Jr, LEROITH D: Role of tyrosine kinase activity in signal transduction by the insulin-like growth factor-I (IGF-1) receptor. Characterization of kinase-deficient IGF-1 receptors and the action of an IGF-1-mimetic antibody (αIR-3 . J. Biol Chem. (1993) 268:2655-2661.
68. MALONEY EK, MCLAUGHLIN JL, DAGDIGIAN NE et al.: An anti-insulin-like growth factor I receptor antibody that is a potent inhibitor of cancer cell proliferation. Cancer Res. (2003) 63 5073-5083.
69. BURTRUM D, ZHU Z, LU D et al.: A fully human monoclonal antibody to the insulin-like growth factor I receptor blocks ligand-dependent signaling and inhibits human tumor growth in vivo. Cancer Res. (2003) 63:8912-8921.
70. GOETSCH L, GONZALEZ A, LEGER O et al.: A recombinant humanized anti-insulin-like growth factor receptor type I antibody (h7C10) enhances the antitumor activity of vinorelbine and anti-epidermal growth factor receptor therapy against human cancer xenografts. Int. J. Cancer (2004)
71. LI SL, LIANG SJ, GUO N, WU AM, FUJITA-YAMAGUCHI Y: Single-chain antibodies against human insulin-like growth factor I receptor: expression, purification, and effect on tumor growth. Cancer Immunol. Immunother. (2000) 49:243-252.
72. PIETRZKOWSKI Z, WERNICKE D, PORCU P, JAMESON BA, BASERGA R: Inhibition of cellular proliferation by peptide analogues of insulin-like growth factor 1. Cancer Res. (1992) 52:6447-6451.
73. PIETRZKOWSKI Z, MULHOLLAND G, GOMELLA L et al.: Inhibition of growth of prostatic cancer cell lines by peptide analogues of insulin-like growth factor 1. Cancer Res. (1993) 53 1102-1106.
74. D'AMBROSIO C, FERBER A, RESNICOFF M, BASERGA R: A soluble insulin-like growth factor I receptor that induces apoptosis of tumor cells in vivo and inhibits tumorigenesis. Cancer Res. (1996) 56:4013-4020.
75. JIANG Y, ROM WN, YIE TA, CHI CX, TCHOU-WONG KM: Induction of tumor suppression and glandular differentiation of A549 lung carcinoma cells by dominant-negative IGF-1 receptor. Oncogene (1999) 18 6071-6077.
76. HONGO A, YUMET G, RESNICOFF M et al.: Inhibition of tumorigenesis and induction of apoptosis in human tumor cells by the stable expression of a myristylated COOH terminus of the insulin-like growth factor I receptor. Cancer Res. (1998) 58:2477-2484.
77. LIU Y, LEHAR S, CORVI C, PAYNE G, O'CONNOR R: Expression of the insulin-like growth factor I receptor C terminus as a myristylated protein leads to induction of apoptosis in tumor cells. Cancer Res. (1998) 58:570-576.
78. McGUIRE WL Jr, JACKSON JG, FIGUEROA JA et al.: Regulation of insulin-like growth factor-binding protein (IGFBP) expression by breast cancer cells: use of IGFBP-1 as an inhibitor of insulin-like growth factor action. J. Natl. Cancer Inst. (1992) 84:1336-1341.
79. FIGUEROA JA, SHARMA J, JACKSON JG et al.: Recombinant insulin-like growth factor binding protein-1 inhibits IGF-1, serum, and estrogen-dependent growth of MCF-7 human breast cancer cells. J. Cell. Physiol. (1993) 157:229-236.
80. YEE D, JACKSON JG, KOZELSKY TW, FIGUEROA JA: Insulin-like growth factor binding protein 1 expression inhibits insulin-like growth factor I action in MCF-7 breast cancer cells. Cell Growth Differ. (1994) 5:73-77.
81. YEE D, VAN DEN BERG CL, KOZELSKY TW, KUHN JG, COX GN: Pharmacokinetic profile of recombination human insulin-like growth factor binding protein-1 in athymic mice. Biomed. Pharmacother. (1996) 50:154-157.
82. VAN DEN BERG CL, COX GN, STROH CA et al.: Polyethylene glycol conjugated insulin-like growth factor binding protein-1 (IGFBP-1) inhibits growth of breast cancer in athymic mice. Eur. J. Cancer (1997) 33:1108-1113.
83. NICKERSON T, HUYNH H, POLLAK M: Insulin-like growth factor binding protein-3 induces apoptosis in MCF7 breast cancer cells. Biochem. Biophys. Pes. Commun. (1997) 237:690-693.
84. FIRTH SM, FANAYAN S, BENN D, BAXTER RC: Development of resistance to insulin-like growth factor binding protein-3 in transfected T47D breast cancer cells. Biochem. Biophys. Res. Commun. (1998) 246:325-329.
85. FOWLER CA, PERKS CM, NEWCOMB PV et al.: Insulin-like growth factor binding protein-3 (IGFBP-3) potentiates paclitaxel-induced apoptosis in human breast cancer cells. Int. J. Cancer (2000) 88 448-453.
86. RAJAH R, VALENTINIS B, COHEN P: Insulin-like growth factor (IGF)-binding protein-3 induces apoptosis and mediates the effects of transforming growth factor-beta1 on programmed cell death through a p53- and IGF-independent mechanism. J. Biol. Chem. (1997) 272 12181-12188.
87. KIM HS, INGERMANN AR, TSUBAKI J et al.: Insulin-like growth factor-binding protein 3 induces caspase-dependent apoptosis through a death receptor-mediated pathway in MCF-7 human breast cancer cells. Cancer Res. (2004) 64:2229-2237.
88. JONES JI, GOCKERMAN A, BUSBY WH Jr, WRIGHT G, CLEMMONS DR: Insulin-like growth factor binding protein 1 stimulates cell migration and binds to the alpha 5 beta 1 integrin by means of its Arg-Gly-Asp sequence. Proc. Natl. Acad. Sci. USA (1993) 90:10553-10557.
89. POLLAK MN, SCHERNHAMMER ES, HANKINSON SE: Insulin-like growth factors and neoplasia. Nat. Rev. Cancer (2004) 4:505-518.
90. WU Y, CUI K, MIYOSHI K et al.: Reduced circulating insulin-like growth factor I levels delay the onset of chemically and genetically induced mammary tumors. Cancer Res. (2003) 63 4384-4388.
91. YANG XF, BEAMER WG, HUYNH H, POLLAK M: Reduced growth of human breast cancer xenografts in hosts homozygous for the lit mutation. Cancer Res. (1996) 56:1509-1511.
92. WU Y, YAKAR S, ZHAO L, HENNIGHAUSEN L, LEROITH D: Circulating insulin-like growth factor-I levels regulate colon cancer growth and metastasis. Cancer Res. (2002) 62:1030-1035.
93. INGLE JN, SUMAN VJ, KARDINAL CG et al.: A randomized trial of tamoxifen alone or combined with octreotide in the treatment of women with metastatic breast carcinoma. Cancer (1999) 85 1284-1292.
94. McCUTCHEON IE, FLYVBJERG A, HILL H et al.: Antitumor activity of the growth hormone receptor antagonist pegvisomant against human meningiomas in nude mice. J. Neurosurg. (2001) 94 487-492.
95. ELLIS MJC, LEAV BA, YANG ZJ et al.: Affinity for the insulin-like growth factor-II (IGF-2) receptor inhibits autocrine IGF-2 activity in MCF-7 breast cancer cells. Mol. Endocrinol. (1996) 10:286-297.
96. VELCULESCU VE, ZHANG L, VOGELSTEIN B, KINZLER KW: Serial analysis of gene expression. Science (1995) 270:484-487.
97. LI X, ADAM G, CUI H et al.: Expression, promoter usage and parental imprinting status of insulin-like growth factor II (IGF2) in human hepatoblastoma: uncoupling of IGF2 and H19 imprinting. Oncogene (1995) 11:221-229.
98. KULL FC, JR:, JACOBS S, SU YF et al.: Monoclonal antibodies to receptors for insulin and somatomedin-C. J. Biol. Chem. (1983) 258:6561-6566.
99. SARUP JC, JOHNSON RM, KING KL et al.: Characterization of an anti-p185HER2 monoclonal antibody that stimulates receptor function and inhibits tumor cell growth. Growth Regul. (1991) 1:72-82.
100. SATO JD, KAWAMOTO T, LE AD et al.: Biological effects in vitro of monoclonal antibodies to human epidermal growth factor receptors. Mol. Biol. Med (1983) 1:511-529.